Trial Evaluating Ambulatory Therapy of Travelers’ Diarrhea (TrEAT TD) Study: A Randomized Controlled Trial Comparing 3 Single-Dose Antibiotic Regimens With Loperamide
Author(s) -
Mark S. Riddle,
Patrick Connor,
Jamie Fraser,
Chad K. Porter,
Brett Swierczewski,
Emma Hutley,
Brook Danboise,
Mark P. Simons,
Christine Hulseberg,
Tahaniyat Lalani,
Ramiro L. Gutiérrez,
David R. Tribble,
Matthew Adam,
Ernest Akorli,
R Armstrong,
Lucy Ashford-Brown,
Jaime Alvarado,
Ricardo Avilés,
Charlotte Ayres,
Timothy Ballard,
L Barry,
Mary Bavaro,
Catherine M Berjohn,
Robert Bjoraker,
Peter Blenkinsop,
Jason Blitz,
Jeromy Boucher,
Timothy Burgess,
Daniel Burns,
Jenna Burns,
Shauna Butler,
Anthony T. Cancio,
Anthony P. Cardile,
Tarah Carnes,
F Cheng,
Katherine Clay,
David J. Cook,
Robert Deiss,
Charles Duffield,
Christopher Duplessis,
Rhonda Dyer,
Aaron Farmer,
Robert Gormley,
Antonia Hazlerigg,
Jewell Hemmings,
Neil Hill,
Emily Hollis,
Jack Hutter,
Alshia Johnson,
Paul Kartchner,
Fred Kency,
Kelly M Latimer,
J Lentaigne,
Andrew G. Letizia,
Jason D. Maguire,
Jennifer Masel,
Ryan C. Maves,
Aline Miura,
Lynette Moore,
Olamide Oladipo,
Shane Patterson,
Mark Pence,
Adrian Proffitt,
Joanna E. Rimmer,
Blanca Rodríguez,
Carlo Riccardo Rossi,
Claire Royston,
Melanie Sanders,
Karen J. Santiago,
Thomas Scorer,
Amanda Self,
Akira Shishido,
Mildred Sitonik,
Daniel Snyder,
Garrick Stride,
Hamilton Tilley,
M Timlin,
Melanie Trado,
Detonya Tulsie,
Lavanya Viswanathan,
Tyler Warkentien,
John Wedgwood,
Samuel J. White
Publication year - 2017
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/cix693
Subject(s) - rifaximin , medicine , azithromycin , levofloxacin , loperamide , nausea , adverse effect , diarrhea , traveler's diarrhea , randomized controlled trial , vomiting , tolerability , antibacterial agent , antibiotics , microbiology and biotechnology , biology
Recommended treatment for travelers' diarrhea includes the combination of an antibiotic, usually a fluoroquinolone or azithromycin, and loperamide for rapid resolution of symptoms. However, adverse events, postdose nausea with high-dose azithromycin, effectiveness of single-dose rifaximin, and emerging resistance to front-line agents are evidence gaps underlying current recommendations.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom